Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO)
Identifieur interne : 000040 ( PascalFrancis/Corpus ); précédent : 000039; suivant : 000041Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO)
Auteurs : Clothilde Lindet ; Agnès Neuville ; Nicolas Penel ; Marick Lae ; Jean-Jacques Michels ; Martine Trassard ; Philippe Terrier ; Isabelle Birtwisle-Peyrottes ; Isabelle Valo ; Françoise Collin ; Marie-Christine Chateau ; Yves-Marie Robin ; Jean-Michel CoindreSource :
- European journal of cancer : (1990) [ 0959-8049 ] ; 2013.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Background: Angiosarcomas represent less than 2% of all adult soft tissue sarcomas. Prognostic factors and the role of (neo-) adjuvant treatments in the management of localised angiosarcomas require further investigation. Methods: We have conducted a retrospective multicenter study (June 1980 to October 2009) of 107 patients with localised angiosarcomas. All of the cases were centrally reviewed by a certified pathologist. Univariate and multivariate analyses were conducted to identify independent poor prognostic factors (PF). Overall survival (OS) and Local Recurrence-Free Survival (LRFS) were estimated using the Kaplan-Meier method. The effect of treatments was explored using the Cox model after adjusting for the PF. Results: The median age was 71 years. 22.4% and 62.6% developed an angiosarcoma in pre-existing lymphoedema and within irradiated tissue respectively. The median OS, LRFS and Disease Recurrence-Free Survival (DRFS) were 38.8, 27 and 36.1 months, respectively. In multivariate analysis, the following parameters influenced the OS: lymphoedema (Hazard ratio (HR) = 2.0) and size >5 cm (HR = 1.5). After adjustment to these PF, RO margins was the only treatment parameter that improving the OS (HR = 0.2). In the multivariate analysis, the LRFS was influenced by an age >70 (HR = 1.8) and pre-existing lymphoedema (HR = 2.0). After adjustment for these PF, RO margins (HR = 0.5) and adjuvant radiotherapy (HR = 0.3) improved the LRFS. Conclusions: Our results suggest the following points: (i) pre-existing lymphoedema, tumour size and age >70 are probably the major prognostic factors in patients with localised angiosarcomas ; (ii) the achievement of RO margins is probably of major importance for improving the patient outcome and (iii) adjuvant radiotherapy probably decreased the risk of local recurrence.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 13-0084494 INIST |
|---|---|
| ET : | Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO) |
| AU : | LINDET (Clothilde); NEUVILLE (Agnès); PENEL (Nicolas); LAE (Marick); MICHELS (Jean-Jacques); TRASSARD (Martine); TERRIER (Philippe); BIRTWISLE-PEYROTTES (Isabelle); VALO (Isabelle); COLLIN (Françoise); CHATEAU (Marie-Christine); ROBIN (Yves-Marie); COINDRE (Jean-Michel) |
| AF : | Department of General Oncology, Oscar Lambret Cancer Center, 3 Rue Combemale/59020 Lille/France (1 aut., 3 aut.); Department of Pathology, Institut Bergonie, 229 Cours Argonne/33000 Bordeaux/France (2 aut., 13 aut.); Department of Pathology, Institut Curie, 26 Rue d'Ulm 75005 Paris/France (4 aut.); Department of Pathology, Centre François Baclesse, Avenue Gen Harris 14000 Caen/France (5 aut.); Department of Pathology, Centre René Huguenin, 35 Rue Dailly 92210 Saint-Cloud/France (6 aut.); Department of Pathology, Institut Gustave Roussy, 39 Rue Camille Desmoulins/94800 Villejuif/France (7 aut.); Department of Pathology, Centre Antoine Lacassagne, 33, avenue de Valombrose 06189 Nice/France (8 aut.); Department of Pathology, Centre Paul Papin, 5 Rue Moll/49000 Angers/France (9 aut.); Department of Pathology, Centre George-François Leclerc, 1 r Prof Marion/21000 Dijon/France (10 aut.); Department of Pathology, Centre Val-d'Aurelle, 31 rue de la Croix Verte/34000 Montpellier/France (11 aut.); Department of Pathology, Centre Oscar Lambret, 3 rue Combemale/59020 Lille/France (12 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | European journal of cancer : (1990); ISSN 0959-8049; Royaume-Uni; Da. 2013; Vol. 49; No. 2; Pp. 369-376; Bibl. 26 ref. |
| LA : | Anglais |
| EA : | Background: Angiosarcomas represent less than 2% of all adult soft tissue sarcomas. Prognostic factors and the role of (neo-) adjuvant treatments in the management of localised angiosarcomas require further investigation. Methods: We have conducted a retrospective multicenter study (June 1980 to October 2009) of 107 patients with localised angiosarcomas. All of the cases were centrally reviewed by a certified pathologist. Univariate and multivariate analyses were conducted to identify independent poor prognostic factors (PF). Overall survival (OS) and Local Recurrence-Free Survival (LRFS) were estimated using the Kaplan-Meier method. The effect of treatments was explored using the Cox model after adjusting for the PF. Results: The median age was 71 years. 22.4% and 62.6% developed an angiosarcoma in pre-existing lymphoedema and within irradiated tissue respectively. The median OS, LRFS and Disease Recurrence-Free Survival (DRFS) were 38.8, 27 and 36.1 months, respectively. In multivariate analysis, the following parameters influenced the OS: lymphoedema (Hazard ratio (HR) = 2.0) and size >5 cm (HR = 1.5). After adjustment to these PF, RO margins was the only treatment parameter that improving the OS (HR = 0.2). In the multivariate analysis, the LRFS was influenced by an age >70 (HR = 1.8) and pre-existing lymphoedema (HR = 2.0). After adjustment for these PF, RO margins (HR = 0.5) and adjuvant radiotherapy (HR = 0.3) improved the LRFS. Conclusions: Our results suggest the following points: (i) pre-existing lymphoedema, tumour size and age >70 are probably the major prognostic factors in patients with localised angiosarcomas ; (ii) the achievement of RO margins is probably of major importance for improving the patient outcome and (iii) adjuvant radiotherapy probably decreased the risk of local recurrence. |
| CC : | 002B02; 002B04 |
| FD : | Angiosarcome; Pronostic; Traitement; Sarcome; Rétrospective; Age; Lymphoedème; Cancérologie |
| FG : | Pathologie de l'appareil circulatoire; Tumeur maligne; Cancer; Pathologie des vaisseaux sanguins; Pathologie des vaisseaux lymphatiques |
| ED : | Angiosarcoma; Prognosis; Treatment; Sarcoma; Retrospective; Age; Lymphedema; Cancerology |
| EG : | Cardiovascular disease; Malignant tumor; Cancer; Vascular disease; Lymphatic vessel disease |
| SD : | Angiosarcoma; Pronóstico; Tratamiento; Sarcoma; Retrospectiva; Edad; Linfedema; Cancerología |
| LO : | INIST-12648.354000182501500120 |
| ID : | 13-0084494 |
Links to Exploration step
Pascal:13-0084494Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO)</title><author><name sortKey="Lindet, Clothilde" sort="Lindet, Clothilde" uniqKey="Lindet C" first="Clothilde" last="Lindet">Clothilde Lindet</name><affiliation><inist:fA14 i1="01"><s1>Department of General Oncology, Oscar Lambret Cancer Center, 3 Rue Combemale</s1><s2>59020 Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Neuville, Agnes" sort="Neuville, Agnes" uniqKey="Neuville A" first="Agnès" last="Neuville">Agnès Neuville</name><affiliation><inist:fA14 i1="02"><s1>Department of Pathology, Institut Bergonie, 229 Cours Argonne</s1><s2>33000 Bordeaux</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Penel, Nicolas" sort="Penel, Nicolas" uniqKey="Penel N" first="Nicolas" last="Penel">Nicolas Penel</name><affiliation><inist:fA14 i1="01"><s1>Department of General Oncology, Oscar Lambret Cancer Center, 3 Rue Combemale</s1><s2>59020 Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lae, Marick" sort="Lae, Marick" uniqKey="Lae M" first="Marick" last="Lae">Marick Lae</name><affiliation><inist:fA14 i1="03"><s1>Department of Pathology, Institut Curie, 26 Rue d'Ulm 75005 Paris</s1><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Michels, Jean Jacques" sort="Michels, Jean Jacques" uniqKey="Michels J" first="Jean-Jacques" last="Michels">Jean-Jacques Michels</name><affiliation><inist:fA14 i1="04"><s1>Department of Pathology, Centre François Baclesse, Avenue Gen Harris 14000 Caen</s1><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Trassard, Martine" sort="Trassard, Martine" uniqKey="Trassard M" first="Martine" last="Trassard">Martine Trassard</name><affiliation><inist:fA14 i1="05"><s1>Department of Pathology, Centre René Huguenin, 35 Rue Dailly 92210 Saint-Cloud</s1><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Terrier, Philippe" sort="Terrier, Philippe" uniqKey="Terrier P" first="Philippe" last="Terrier">Philippe Terrier</name><affiliation><inist:fA14 i1="06"><s1>Department of Pathology, Institut Gustave Roussy, 39 Rue Camille Desmoulins</s1><s2>94800 Villejuif</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Birtwisle Peyrottes, Isabelle" sort="Birtwisle Peyrottes, Isabelle" uniqKey="Birtwisle Peyrottes I" first="Isabelle" last="Birtwisle-Peyrottes">Isabelle Birtwisle-Peyrottes</name><affiliation><inist:fA14 i1="07"><s1>Department of Pathology, Centre Antoine Lacassagne, 33, avenue de Valombrose 06189 Nice</s1><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Valo, Isabelle" sort="Valo, Isabelle" uniqKey="Valo I" first="Isabelle" last="Valo">Isabelle Valo</name><affiliation><inist:fA14 i1="08"><s1>Department of Pathology, Centre Paul Papin, 5 Rue Moll</s1><s2>49000 Angers</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Collin, Francoise" sort="Collin, Francoise" uniqKey="Collin F" first="Françoise" last="Collin">Françoise Collin</name><affiliation><inist:fA14 i1="09"><s1>Department of Pathology, Centre George-François Leclerc, 1 r Prof Marion</s1><s2>21000 Dijon</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chateau, Marie Christine" sort="Chateau, Marie Christine" uniqKey="Chateau M" first="Marie-Christine" last="Chateau">Marie-Christine Chateau</name><affiliation><inist:fA14 i1="10"><s1>Department of Pathology, Centre Val-d'Aurelle, 31 rue de la Croix Verte</s1><s2>34000 Montpellier</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Robin, Yves Marie" sort="Robin, Yves Marie" uniqKey="Robin Y" first="Yves-Marie" last="Robin">Yves-Marie Robin</name><affiliation><inist:fA14 i1="11"><s1>Department of Pathology, Centre Oscar Lambret, 3 rue Combemale</s1><s2>59020 Lille</s2><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Coindre, Jean Michel" sort="Coindre, Jean Michel" uniqKey="Coindre J" first="Jean-Michel" last="Coindre">Jean-Michel Coindre</name><affiliation><inist:fA14 i1="02"><s1>Department of Pathology, Institut Bergonie, 229 Cours Argonne</s1><s2>33000 Bordeaux</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">13-0084494</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 13-0084494 INIST</idno><idno type="RBID">Pascal:13-0084494</idno><idno type="wicri:Area/PascalFrancis/Corpus">000040</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO)</title><author><name sortKey="Lindet, Clothilde" sort="Lindet, Clothilde" uniqKey="Lindet C" first="Clothilde" last="Lindet">Clothilde Lindet</name><affiliation><inist:fA14 i1="01"><s1>Department of General Oncology, Oscar Lambret Cancer Center, 3 Rue Combemale</s1><s2>59020 Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Neuville, Agnes" sort="Neuville, Agnes" uniqKey="Neuville A" first="Agnès" last="Neuville">Agnès Neuville</name><affiliation><inist:fA14 i1="02"><s1>Department of Pathology, Institut Bergonie, 229 Cours Argonne</s1><s2>33000 Bordeaux</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Penel, Nicolas" sort="Penel, Nicolas" uniqKey="Penel N" first="Nicolas" last="Penel">Nicolas Penel</name><affiliation><inist:fA14 i1="01"><s1>Department of General Oncology, Oscar Lambret Cancer Center, 3 Rue Combemale</s1><s2>59020 Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lae, Marick" sort="Lae, Marick" uniqKey="Lae M" first="Marick" last="Lae">Marick Lae</name><affiliation><inist:fA14 i1="03"><s1>Department of Pathology, Institut Curie, 26 Rue d'Ulm 75005 Paris</s1><s3>FRA</s3><sZ>4 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Michels, Jean Jacques" sort="Michels, Jean Jacques" uniqKey="Michels J" first="Jean-Jacques" last="Michels">Jean-Jacques Michels</name><affiliation><inist:fA14 i1="04"><s1>Department of Pathology, Centre François Baclesse, Avenue Gen Harris 14000 Caen</s1><s3>FRA</s3><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Trassard, Martine" sort="Trassard, Martine" uniqKey="Trassard M" first="Martine" last="Trassard">Martine Trassard</name><affiliation><inist:fA14 i1="05"><s1>Department of Pathology, Centre René Huguenin, 35 Rue Dailly 92210 Saint-Cloud</s1><s3>FRA</s3><sZ>6 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Terrier, Philippe" sort="Terrier, Philippe" uniqKey="Terrier P" first="Philippe" last="Terrier">Philippe Terrier</name><affiliation><inist:fA14 i1="06"><s1>Department of Pathology, Institut Gustave Roussy, 39 Rue Camille Desmoulins</s1><s2>94800 Villejuif</s2><s3>FRA</s3><sZ>7 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Birtwisle Peyrottes, Isabelle" sort="Birtwisle Peyrottes, Isabelle" uniqKey="Birtwisle Peyrottes I" first="Isabelle" last="Birtwisle-Peyrottes">Isabelle Birtwisle-Peyrottes</name><affiliation><inist:fA14 i1="07"><s1>Department of Pathology, Centre Antoine Lacassagne, 33, avenue de Valombrose 06189 Nice</s1><s3>FRA</s3><sZ>8 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Valo, Isabelle" sort="Valo, Isabelle" uniqKey="Valo I" first="Isabelle" last="Valo">Isabelle Valo</name><affiliation><inist:fA14 i1="08"><s1>Department of Pathology, Centre Paul Papin, 5 Rue Moll</s1><s2>49000 Angers</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Collin, Francoise" sort="Collin, Francoise" uniqKey="Collin F" first="Françoise" last="Collin">Françoise Collin</name><affiliation><inist:fA14 i1="09"><s1>Department of Pathology, Centre George-François Leclerc, 1 r Prof Marion</s1><s2>21000 Dijon</s2><s3>FRA</s3><sZ>10 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Chateau, Marie Christine" sort="Chateau, Marie Christine" uniqKey="Chateau M" first="Marie-Christine" last="Chateau">Marie-Christine Chateau</name><affiliation><inist:fA14 i1="10"><s1>Department of Pathology, Centre Val-d'Aurelle, 31 rue de la Croix Verte</s1><s2>34000 Montpellier</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Robin, Yves Marie" sort="Robin, Yves Marie" uniqKey="Robin Y" first="Yves-Marie" last="Robin">Yves-Marie Robin</name><affiliation><inist:fA14 i1="11"><s1>Department of Pathology, Centre Oscar Lambret, 3 rue Combemale</s1><s2>59020 Lille</s2><s3>FRA</s3><sZ>12 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Coindre, Jean Michel" sort="Coindre, Jean Michel" uniqKey="Coindre J" first="Jean-Michel" last="Coindre">Jean-Michel Coindre</name><affiliation><inist:fA14 i1="02"><s1>Department of Pathology, Institut Bergonie, 229 Cours Argonne</s1><s2>33000 Bordeaux</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>13 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">European journal of cancer : (1990)</title><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><idno type="ISSN">0959-8049</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">European journal of cancer : (1990)</title><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><idno type="ISSN">0959-8049</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age</term><term>Angiosarcoma</term><term>Cancerology</term><term>Lymphedema</term><term>Prognosis</term><term>Retrospective</term><term>Sarcoma</term><term>Treatment</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Angiosarcome</term><term>Pronostic</term><term>Traitement</term><term>Sarcome</term><term>Rétrospective</term><term>Age</term><term>Lymphoedème</term><term>Cancérologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Angiosarcomas represent less than 2% of all adult soft tissue sarcomas. Prognostic factors and the role of (neo-) adjuvant treatments in the management of localised angiosarcomas require further investigation. Methods: We have conducted a retrospective multicenter study (June 1980 to October 2009) of 107 patients with localised angiosarcomas. All of the cases were centrally reviewed by a certified pathologist. Univariate and multivariate analyses were conducted to identify independent poor prognostic factors (PF). Overall survival (OS) and Local Recurrence-Free Survival (LRFS) were estimated using the Kaplan-Meier method. The effect of treatments was explored using the Cox model after adjusting for the PF. Results: The median age was 71 years. 22.4% and 62.6% developed an angiosarcoma in pre-existing lymphoedema and within irradiated tissue respectively. The median OS, LRFS and Disease Recurrence-Free Survival (DRFS) were 38.8, 27 and 36.1 months, respectively. In multivariate analysis, the following parameters influenced the OS: lymphoedema (Hazard ratio (HR) = 2.0) and size >5 cm (HR = 1.5). After adjustment to these PF, RO margins was the only treatment parameter that improving the OS (HR = 0.2). In the multivariate analysis, the LRFS was influenced by an age >70 (HR = 1.8) and pre-existing lymphoedema (HR = 2.0). After adjustment for these PF, RO margins (HR = 0.5) and adjuvant radiotherapy (HR = 0.3) improved the LRFS. Conclusions: Our results suggest the following points: (i) pre-existing lymphoedema, tumour size and age >70 are probably the major prognostic factors in patients with localised angiosarcomas ; (ii) the achievement of RO margins is probably of major importance for improving the patient outcome and (iii) adjuvant radiotherapy probably decreased the risk of local recurrence.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0959-8049</s0></fA01><fA03 i2="1"><s0>Eur. j. cancer : (1990)</s0></fA03><fA05><s2>49</s2></fA05><fA06><s2>2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO)</s1></fA08><fA11 i1="01" i2="1"><s1>LINDET (Clothilde)</s1></fA11><fA11 i1="02" i2="1"><s1>NEUVILLE (Agnès)</s1></fA11><fA11 i1="03" i2="1"><s1>PENEL (Nicolas)</s1></fA11><fA11 i1="04" i2="1"><s1>LAE (Marick)</s1></fA11><fA11 i1="05" i2="1"><s1>MICHELS (Jean-Jacques)</s1></fA11><fA11 i1="06" i2="1"><s1>TRASSARD (Martine)</s1></fA11><fA11 i1="07" i2="1"><s1>TERRIER (Philippe)</s1></fA11><fA11 i1="08" i2="1"><s1>BIRTWISLE-PEYROTTES (Isabelle)</s1></fA11><fA11 i1="09" i2="1"><s1>VALO (Isabelle)</s1></fA11><fA11 i1="10" i2="1"><s1>COLLIN (Françoise)</s1></fA11><fA11 i1="11" i2="1"><s1>CHATEAU (Marie-Christine)</s1></fA11><fA11 i1="12" i2="1"><s1>ROBIN (Yves-Marie)</s1></fA11><fA11 i1="13" i2="1"><s1>COINDRE (Jean-Michel)</s1></fA11><fA14 i1="01"><s1>Department of General Oncology, Oscar Lambret Cancer Center, 3 Rue Combemale</s1><s2>59020 Lille</s2><s3>FRA</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>Department of Pathology, Institut Bergonie, 229 Cours Argonne</s1><s2>33000 Bordeaux</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>13 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Pathology, Institut Curie, 26 Rue d'Ulm 75005 Paris</s1><s3>FRA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Pathology, Centre François Baclesse, Avenue Gen Harris 14000 Caen</s1><s3>FRA</s3><sZ>5 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Pathology, Centre René Huguenin, 35 Rue Dailly 92210 Saint-Cloud</s1><s3>FRA</s3><sZ>6 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Pathology, Institut Gustave Roussy, 39 Rue Camille Desmoulins</s1><s2>94800 Villejuif</s2><s3>FRA</s3><sZ>7 aut.</sZ></fA14><fA14 i1="07"><s1>Department of Pathology, Centre Antoine Lacassagne, 33, avenue de Valombrose 06189 Nice</s1><s3>FRA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="08"><s1>Department of Pathology, Centre Paul Papin, 5 Rue Moll</s1><s2>49000 Angers</s2><s3>FRA</s3><sZ>9 aut.</sZ></fA14><fA14 i1="09"><s1>Department of Pathology, Centre George-François Leclerc, 1 r Prof Marion</s1><s2>21000 Dijon</s2><s3>FRA</s3><sZ>10 aut.</sZ></fA14><fA14 i1="10"><s1>Department of Pathology, Centre Val-d'Aurelle, 31 rue de la Croix Verte</s1><s2>34000 Montpellier</s2><s3>FRA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="11"><s1>Department of Pathology, Centre Oscar Lambret, 3 rue Combemale</s1><s2>59020 Lille</s2><s3>FRA</s3><sZ>12 aut.</sZ></fA14><fA20><s1>369-376</s1></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>12648</s2><s5>354000182501500120</s5></fA43><fA44><s0>0000</s0><s1>© 2013 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>26 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>13-0084494</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>European journal of cancer : (1990)</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Background: Angiosarcomas represent less than 2% of all adult soft tissue sarcomas. Prognostic factors and the role of (neo-) adjuvant treatments in the management of localised angiosarcomas require further investigation. Methods: We have conducted a retrospective multicenter study (June 1980 to October 2009) of 107 patients with localised angiosarcomas. All of the cases were centrally reviewed by a certified pathologist. Univariate and multivariate analyses were conducted to identify independent poor prognostic factors (PF). Overall survival (OS) and Local Recurrence-Free Survival (LRFS) were estimated using the Kaplan-Meier method. The effect of treatments was explored using the Cox model after adjusting for the PF. Results: The median age was 71 years. 22.4% and 62.6% developed an angiosarcoma in pre-existing lymphoedema and within irradiated tissue respectively. The median OS, LRFS and Disease Recurrence-Free Survival (DRFS) were 38.8, 27 and 36.1 months, respectively. In multivariate analysis, the following parameters influenced the OS: lymphoedema (Hazard ratio (HR) = 2.0) and size >5 cm (HR = 1.5). After adjustment to these PF, RO margins was the only treatment parameter that improving the OS (HR = 0.2). In the multivariate analysis, the LRFS was influenced by an age >70 (HR = 1.8) and pre-existing lymphoedema (HR = 2.0). After adjustment for these PF, RO margins (HR = 0.5) and adjuvant radiotherapy (HR = 0.3) improved the LRFS. Conclusions: Our results suggest the following points: (i) pre-existing lymphoedema, tumour size and age >70 are probably the major prognostic factors in patients with localised angiosarcomas ; (ii) the achievement of RO margins is probably of major importance for improving the patient outcome and (iii) adjuvant radiotherapy probably decreased the risk of local recurrence.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02</s0></fC02><fC02 i1="02" i2="X"><s0>002B04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Angiosarcome</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Angiosarcoma</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Angiosarcoma</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Pronostic</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Prognosis</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Pronóstico</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Traitement</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Treatment</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Tratamiento</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Sarcome</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Sarcoma</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Sarcoma</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Rétrospective</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Retrospective</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Retrospectiva</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Age</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Age</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Edad</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Lymphoedème</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Lymphedema</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Linfedema</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Cancérologie</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Cancerology</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Cancerología</s0><s5>08</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie des vaisseaux sanguins</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Vascular disease</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Vaso sanguíneo patología</s0><s5>39</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Linfático patología</s0><s5>40</s5></fC07><fN21><s1>056</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 13-0084494 INIST</NO><ET>Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO)</ET><AU>LINDET (Clothilde); NEUVILLE (Agnès); PENEL (Nicolas); LAE (Marick); MICHELS (Jean-Jacques); TRASSARD (Martine); TERRIER (Philippe); BIRTWISLE-PEYROTTES (Isabelle); VALO (Isabelle); COLLIN (Françoise); CHATEAU (Marie-Christine); ROBIN (Yves-Marie); COINDRE (Jean-Michel)</AU><AF>Department of General Oncology, Oscar Lambret Cancer Center, 3 Rue Combemale/59020 Lille/France (1 aut., 3 aut.); Department of Pathology, Institut Bergonie, 229 Cours Argonne/33000 Bordeaux/France (2 aut., 13 aut.); Department of Pathology, Institut Curie, 26 Rue d'Ulm 75005 Paris/France (4 aut.); Department of Pathology, Centre François Baclesse, Avenue Gen Harris 14000 Caen/France (5 aut.); Department of Pathology, Centre René Huguenin, 35 Rue Dailly 92210 Saint-Cloud/France (6 aut.); Department of Pathology, Institut Gustave Roussy, 39 Rue Camille Desmoulins/94800 Villejuif/France (7 aut.); Department of Pathology, Centre Antoine Lacassagne, 33, avenue de Valombrose 06189 Nice/France (8 aut.); Department of Pathology, Centre Paul Papin, 5 Rue Moll/49000 Angers/France (9 aut.); Department of Pathology, Centre George-François Leclerc, 1 r Prof Marion/21000 Dijon/France (10 aut.); Department of Pathology, Centre Val-d'Aurelle, 31 rue de la Croix Verte/34000 Montpellier/France (11 aut.); Department of Pathology, Centre Oscar Lambret, 3 rue Combemale/59020 Lille/France (12 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>European journal of cancer : (1990); ISSN 0959-8049; Royaume-Uni; Da. 2013; Vol. 49; No. 2; Pp. 369-376; Bibl. 26 ref.</SO><LA>Anglais</LA><EA>Background: Angiosarcomas represent less than 2% of all adult soft tissue sarcomas. Prognostic factors and the role of (neo-) adjuvant treatments in the management of localised angiosarcomas require further investigation. Methods: We have conducted a retrospective multicenter study (June 1980 to October 2009) of 107 patients with localised angiosarcomas. All of the cases were centrally reviewed by a certified pathologist. Univariate and multivariate analyses were conducted to identify independent poor prognostic factors (PF). Overall survival (OS) and Local Recurrence-Free Survival (LRFS) were estimated using the Kaplan-Meier method. The effect of treatments was explored using the Cox model after adjusting for the PF. Results: The median age was 71 years. 22.4% and 62.6% developed an angiosarcoma in pre-existing lymphoedema and within irradiated tissue respectively. The median OS, LRFS and Disease Recurrence-Free Survival (DRFS) were 38.8, 27 and 36.1 months, respectively. In multivariate analysis, the following parameters influenced the OS: lymphoedema (Hazard ratio (HR) = 2.0) and size >5 cm (HR = 1.5). After adjustment to these PF, RO margins was the only treatment parameter that improving the OS (HR = 0.2). In the multivariate analysis, the LRFS was influenced by an age >70 (HR = 1.8) and pre-existing lymphoedema (HR = 2.0). After adjustment for these PF, RO margins (HR = 0.5) and adjuvant radiotherapy (HR = 0.3) improved the LRFS. Conclusions: Our results suggest the following points: (i) pre-existing lymphoedema, tumour size and age >70 are probably the major prognostic factors in patients with localised angiosarcomas ; (ii) the achievement of RO margins is probably of major importance for improving the patient outcome and (iii) adjuvant radiotherapy probably decreased the risk of local recurrence.</EA><CC>002B02; 002B04</CC><FD>Angiosarcome; Pronostic; Traitement; Sarcome; Rétrospective; Age; Lymphoedème; Cancérologie</FD><FG>Pathologie de l'appareil circulatoire; Tumeur maligne; Cancer; Pathologie des vaisseaux sanguins; Pathologie des vaisseaux lymphatiques</FG><ED>Angiosarcoma; Prognosis; Treatment; Sarcoma; Retrospective; Age; Lymphedema; Cancerology</ED><EG>Cardiovascular disease; Malignant tumor; Cancer; Vascular disease; Lymphatic vessel disease</EG><SD>Angiosarcoma; Pronóstico; Tratamiento; Sarcoma; Retrospectiva; Edad; Linfedema; Cancerología</SD><LO>INIST-12648.354000182501500120</LO><ID>13-0084494</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000040 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000040 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:13-0084494
|texte= Localised angiosarcomas: The identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO)
}}
| This area was generated with Dilib version V0.6.31. |  |